The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Therapeutic strategies for Alzheimer's disease in clinical trials
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 2×
“such as ARIA, where solanezumab compares favorably with bapineuzumab [12,19].”
BackgroundResultAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“According to the b-amyloid hypothesis proposed in 1991, NFT formation is preceded by the aggregation of b-amyloid [53].”
MethodGeneration and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
Mammalian Gene Collection (MGC) Program Team* (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242603899 · Cited by 1,749
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,290
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
The worldwide economic impact of dementia 2010
Wimo, A., Jönsson, L., Bond, J., Prince, M., Winblad, B., & International, A. D. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.006 · Cited by 1,141
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703 · cited 1×
“In addition to involvement in the amyloidogenic metabolism of APP, as in the case of g-secretase, it also plays an important role in the metabolism of other proteins, including neuregulin 1 (NGR1), responsible for myelination of neurons [41].”
BackgroundSchneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Targeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, R., & Vassar, R. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 630
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536
Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey II, W. H., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13309 · Cited by 521
Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 16×
“Abbreviations: ACh, acetylcholine; AD, Alzheimer’s disease; ADAM, disintegrin and metalloproteinase domain; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive; ADCS ADL23, Alzheimer’s Disease Cooperative Study – Activities of Daily Living Scale; ADCS-CGIC, Alzheimer’s Disease Cooperative Study – Clinical Global…”
BackgroundInfluentialThe Many Substrates of Presenilin/γ-Secretase
Haapasalo, A., & Kovacs, D. M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101065 · Cited by 458
Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · cited 1×
“A multilevel connection between deposits and soluble oligomers of Ab and progressive phosphorylation of the Tau protein is a strong argument for the validity and integrity of both theories in the development of AD [49].”
BackgroundTreatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323 · cited 1×
“New alternative approaches involve multi-target-directed ligands where a specially designed compound is able to interact with more than one biological target involved in the pathogenesis of AD [103].”
BackgroundSelf-citationWinblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 310
Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons
Kuhn, P., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., Volbracht, C., Schepers, U., Imhof, A., Hoffmeister, A., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.173 · Cited by 301
The histamine H3receptor: an attractive target for the treatment of cognitive disorders
Esbenshade, T. A., Browman, K. E., Bitner, R. S., Strakhova, M., Cowart, M. D., & Brioni, J. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.147 · Cited by 296
Abbas, T., Faivre, E., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282
Memantine: A Review of Its Use in Alzheimer’s Disease
Robinson, D. M., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00015 · Cited by 277
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
Tau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 262
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · cited 1×
“Phase I clinical trials have started and ACI-35 is currently undergoing phase Ib clinical trials in patients suffering from this common form of dementia [56,59].”
BackgroundFrontline therapy of multiple myeloma
Moreau, P., Attal, M., & Facon, T. (2015) · Blood · doi:10.1182/blood-2014-09-568915 · Cited by 244
Going new places using an old MAP: tau, microtubules and human neurodegenerative disease
Garcia, M. L., & Cleveland, D. W. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00172-1 · Cited by 235
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Prickaerts, J., van Goethem, N. P., Chesworth, R., Shapiro, G., Boess, F. G., Methfessel, C., Reneerkens, O. A. H., Flood, D. G., Hilt, D., Gawryl, M., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.024 · Cited by 204
Amyloid‐ß‐directed immunotherapy for Alzheimer's disease
Lannfelt, L., Relkin, N. R., & Siemers, E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 187
Pathways to Alzheimer's disease
Hardy, J., Bogdanovic, N., Winblad, B., Portelius, E., Andreasen, N., Cedazo‐Minguez, A., & Zetterberg, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12192 · Cited by 176
The genetics of Alzheimer's disease
Bagyinszky, E., Youn, Y. C., An, S., & Kim, S. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s51571 · Cited by 173
Wilkinson, D., Windfeld, K., & Colding-Jørgensen, E. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70198-x · Cited by 164
Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163
A 4-Mb High-Density Single Nucleotide Polymorphism-Based Map around Human APOE
Lai, E., Riley, J., Purvis, I., & Roses, A. (1998) · Genomics · doi:10.1006/geno.1998.5581 · Cited by 161
Molecular connexions between dementia and diabetes
Cole, A. R., Astell, A., Green, C., & Sutherland, C. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.04.004 · Cited by 159
Treatment Strategies Targeting Amyloid -Protein
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 153
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, A. H., Grimes, I., Galasko, D. R., Aisen, P. S. S., Sabbagh, M. N., & Mjalli, A. M. M. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-12 · Cited by 144
Therapeutic Potential of γ -Secretase Inhibitors and Modulators
Imbimbo, B. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783334015 · Cited by 143
The role of thalidomide in the management of erythema nodosum leprosum
Walker, S. L., Waters, M. F., & Lockwood, D. N. J. (2007) · Leprosy Review · doi:10.47276/lr.78.3.197 · Cited by 140
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
Mills, S., Mallmann, J., Santacruz, A. M., Fuqua, A., Carril, M. M. G., Aisen, P. S., Althage, M. C., Belyew, S., Benzinger, T. L. S., Brooks, W. S., et al. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.017 · Cited by 139
Intranasal Insulin Ameliorates Tau Hyperphosphorylation in a Rat Model of Type 2 Diabetes
Yang, Y., Ma, D., Wang, Y., Jiang, T., Hu, S., Zhang, M., Yu, X., & Gong, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121294 · Cited by 126
Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 117
Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 114
Disease-modifying drugs in Alzheimer's disease
Scarpini, E. A., Galimberti, D., & Ghezzi, L. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41431 · Cited by 113
Immunotherapy for Alzheimer's disease
Wısnıewskı, T., & Goñi, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.020 · Cited by 112
Grove, R. A., Harrington, C. M., Mahler, A., Beresford, I. J. M., Maruff, P. T., Lowy, M. T., Nicholls, A. J., Boardley, R., Berges, A., Nathan, P. J., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212110148 · Cited by 109
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000041 · Cited by 106
Gabbita, S. P., Srivastava, M. K., Eslami, P., Johnson, M. F., Kobritz, N., Tweedie, D., Greig, N. H., Zemlan, F. P., Sharma, S. P., & Harris‐White, M. E. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-99 · Cited by 104
The complexities of the pathology–pathogenesis relationship in Alzheimer disease
Castellani, R. J., & Perry, G. L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.009 · Cited by 101
Jia, Q., Deng, Y., & Qing, H. (2014) · BioMed Research International · doi:10.1155/2014/837157 · Cited by 96
Lessons from a BACE1 inhibitor trial: Off‐site but not off base
Lahiri, D. K., Maloney, B., Long, J. M., & Greig, N. H. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.11.004 · Cited by 92
Ayutyanont, N., Langbaum, J. B. S., Hendrix, S. B., Chen, K., Fleisher, A., Friesenhahn, M. J., Ward, M. E., Aguirre, C., Acosta‐Baena, N., Madrigal, L., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08927 · Cited by 86
Mikulca, J. A., Nguyen, V., Gajdosik, D. A., Teklu, S. G., Giunta, E. A., Lessa, E. A., Tran, C. H., Terak, E. C., & Raffa, R. B. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12112 · Cited by 82
Egefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 80
Marcos, B., Chuang, T. T., Gil-Bea, F. J., & Ramírez, M. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.281 · Cited by 79
A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Haig, G. M., Pritchett, Y., Meier, A., Othman, A. A., Hall, C. M., Gault, L. M., & Lenz, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140291 · Cited by 78
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease
Relkin, N. R. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0041-4 · Cited by 67
[Gamma-secretase inhibitors and modulators].
Iwai, A. (2011) · PubMed · Cited by 63
Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations
Linnertz, C. L., Saunders, A. M., Lutz, M. W., Crenshaw, D. G., Grossman, I., Burns, D. K., Whitfield, K. E., Hauser, M. A., McCarthy, J. J., Carnes, M. U., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030994 · Cited by 61
New applications of disease genetics and pharmacogenetics to drug development
Roses, A. D., Saunders, A. M., Lutz, M. W., Zhang, N., Hariri, A. R., Asin, K. E., Crenshaw, D. G., Budur, K. S., Burns, D. K., & Brannan, S. K. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.12.002 · Cited by 61
New Approaches to Treating Alzheimer's Disease
Zheng, H., Fridkin, M., & Youdim, M. B. H. (2015) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s13210 · Cited by 59
Sáez-Orellana, F., Godoy, P. A., Bastidas, C. Y., Silva-Grecchi, T., Guzmán, L., Aguayo, L. G., & Fuentealba, J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.005 · Cited by 53
Esbenshade, T. A., Browman, K. E., Miller, T. R., Krueger, K. M., Komater, V. A., Zhang, M., Fox, G. B., Rueter, L. E., Robb, H. M., Radek, R. J., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194126 · Cited by 50
LAWLOR, B. A., Kennelly, S., O'Dwyer, S., Cregg, F., Walsh, C., Coen, R. F., Kenny, R. A., Howard, R. J., Murphy, C., Adams, J., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006364 · Cited by 50
Thalidomide-based TNF-α inhibitors for neurodegenerative diseases
Greig, N. H., Giordano, T., Zhu, X., Yu, Q., Perry, T., Holloway, H. W., Brossi, A. R., Rogers, J. T., Sambamurti, K., & Lahiri, D. K. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1486 · Cited by 45
Effect of active A β immunotherapy on neurons in human Alzheimer's disease
Paquet, C., Amin, J., Mouton‐Liger, F., Nasser, M., Love, S., Gray, F., Pickering, R. M., Nicoll, J. A., Holmes, C., Hugon, J., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4491 · Cited by 44
Invited review: Drug development for tauopathies
Grüninger, F. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12192 · Cited by 40
Leyhe, T., Andreasen, N., Simeoni, M., Reich, A., Arnim, C. A. F. V., Tong, X., Yeo, A. J. M., Khan, S. A., Loercher, A. E., Chalker, M., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt249 · Cited by 36
Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects
Marcos, B., Cabero, M., Solas, M., Aisa, B., & Ramírez, M. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570999054x · Cited by 36
ADAM10 in Synaptic Physiology and Pathology
Musardo, S., Marcello, E. E., Gardoni, F., & Luca, M. D. (2013) · Neurodegenerative Diseases · doi:10.1159/000354233 · Cited by 30
Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease
Han, S.-H., & Mook‐Jung, I. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.7.893 · Cited by 26
Lundkvist, J., Halldin, M. M., Sandin, J., Nordvall, G., Forsell, P. K. A. L., Svensson, S., Jansson, L., Johansson, G., Winblad, B. G., & Ekstrand, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00102 · Cited by 22
The Pathogenesis of Alzheimer's Disease and the Role of Aβ42
Golde, T. E. (2007) · CNS Spectrums · doi:10.1017/s1092852900025876 · Cited by 21
Idalopirdine for Alzheimer's disease: written in the stars
Schneider, L. S. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70232-7 · Cited by 18
Arai, H., Suzuki, H., Yoshiyama, T., Lobello, K., Peng, Y., Liu, E., Ketter, N., Margolin, R. A., Jackson, N. M., & Fujimoto, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.564 · Cited by 18
Hsu, C., Hsu, C., Lee, J. Y., Kuo, Y., & Pai, M. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.07.012 · Cited by 18
Othman, A. A., Haig, G. M., Florian, H., Locke, C. S., Gertsik, L., & Dutta, S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12281 · Cited by 17
Novák, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.246 · Cited by 14
Le système histaminergique : une cible pour de nouveaux traitements des deficits cognitifs
Motawaj, M., Burban, A., Davenas, E., Gbahou, F., Faucard, R., Morisset‐Lopez, S., & Arrang, J. (2010) · Therapies · doi:10.2515/therapie/2010058 · Cited by 9
Wilkinson, D. G., Colding‐Jørgensen, E., & Windfeld, K. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.267 · Cited by 8
del Ser, T., Lovestone, S., Boada, M., Dubois, B., Hüll, M., Rinne, J. O., & León, T. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.359 · Cited by 6
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Targeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease
Kaur, D., Sharma, V., & Deshmukh, R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 484
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Metadata
- Authors
- Godyń, J., Jończyk, J., Panek, D., & Malawska, B.
- Venue
- Pharmacological Reports
- Published
- 2016-02
- Volume
- 68
- Issue
- 1
- Pages
- 127-138
- ISSN
- 1734-1140 (ISSN-L)
- OpenAlex
- W1447565288
- Cited by
- 452
- References
- 101
- FWCI
- 32.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.